Hip Replacement News and Research

RSS

Bone stem cells could become a part of new, innovative hip replacement treatment

Bone stem cells could in future be used instead of bone from donors as part of an innovative new hip replacement treatment, according to scientists at the University of Southampton.

24 Mar 2010

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B clinical study to evaluate the safety and efficacy of PMX-60056 in reversing the anticoagulant activity of low molecule weight heparin (LMWH).

19 Mar 2010

Zimmer Holdings showcases Continuum Acetabular Cup System at AAOS 2010

Zimmer Holdings, Inc., a leader in musculoskeletal care, today showcased its recently introduced Continuum Acetabular Cup System at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting. The Continuum Cup combines the best of Zimmer's proven hip technologies – Trabecular Metal™ Technology, Metasul® Metal-on-Metal technology, BIOLOX® delta and Longevity® Highly Crosslinked Polyethylene – with new innovations in what is now the company's most versatile acetabular cup system.

12 Mar 2010

Study examines discrepancies in patient and physician expectation with joint replacement surgeries

While physicians strive to set realistic expectations for patients undergoing knee and hip joint replacements, a new study reveals that doctor and patient expectations are sometimes not aligned.

11 Mar 2010

Study: Hip replacement patients with MoM implants pass metal ions to their infants during pregnancy

Hip replacement patients with metal-on-metal (MoM) implants (both the socket and hip ball are metal) pass metal ions to their infants during pregnancy, according to a new study presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons.

10 Mar 2010

Orthopaedic Synergy enters into letter of intent and period of exclusivity to acquire Praxim, SA

Orthopaedic Synergy, Inc., is pleased to announce that it has entered into a letter of intent and period of exclusivity to acquire Praxim, SA of France.

10 Mar 2010

Presentation of results from open-label extension study of Xenazine

Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.

6 Mar 2010

Stryker Orthopaedics introduces ADM X3 Mobile Bearing Acetabular System for hip replacement surgery

Stryker Orthopaedics today announced the release of the ADM X3 Mobile Bearing Acetabular System, a next-generation technology for hip replacement surgery designed to minimize the risks associated with total hip replacement surgery.

From Stryker 5 Mar 2010

Porter Adventist Hospital designated as Blue Distinction Center for spine surgery, knee and hip replacement programs

Porter Adventist Hospital is among the first in the country to receive designation as Blue Distinction Centers in two surgical services that have recently been added to the Blue Cross and Blue Shield Association's expansion of its Blue Distinction® designation.

5 Mar 2010

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Canyon PharmaceuticalsTM (www.canyonpharma.com) today announced the availability of Iprivask (desirudin for injection), the first direct thrombin inhibitor (DTI) approved in the United States by the Food and Drug Administration for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism in patients undergoing elective hip replacement surgery.

2 Mar 2010

Stryker Interventional Spine announces the U.S. launch of VertaPlex HV bone cement for VCFs

Stryker Interventional Spine today announced the U.S. launch of VertaPlex® HV. VertaPlex HV is a high viscosity bone cement for use in treating vertebral compression fractures.

From Stryker 2 Mar 2010

HealthGrades America’s 50 Best Hospitals for 2010 identified

The HealthGrades America’s 50 Best Hospitals for 2010 were identified in a report issued today by the leading independent healthcare ratings organization. The analysis, which examined objective patient outcomes over three years at all 5,000 of the nation’s nonfederal hospitals, found that the 50 Best Hospitals had mortality rates that were, on average, 27% lower than other hospitals.

25 Feb 2010

HealthGrades names Good Samaritan Hospital as One of America’s 50 Best Hospitals in 2010

Good Samaritan Hospital in Los Angeles is named as One of America’s 50 Best Hospitals in 2010 by HealthGrades, Inc., the nation’s leading independent healthcare ratings organization.

24 Feb 2010

Amedica, Orthopaedic Synergy sign SiN articulating hip and knee implant Joint Venture Development Agreement

Amedica Corporation (AC), a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today an agreement with Orthopaedic Synergy, Inc. (OSI), a holding company for OMNIlife Science™ and Enztec, both global designers, manufacturers and distributors of leading edge reconstructive surgery implants and instrumentation.

22 Feb 2010

Exeter Hospital designated as 'Blue Distinction Center for Knee and Hip Replacement'

Citing clinical expertise and quality of care, Anthem Blue Cross and Blue Shield in New Hampshire has designated Exeter Hospital as a Blue Distinction Center for Knee and Hip Replacement(SM).

11 Feb 2010

Stryker Orthopaedics announces the release of Rejuvenate Modular Primary Hip System

Stryker Orthopaedics today announced the release of its Rejuvenate Modular Primary Hip System, which is designed to help recreate the anatomy and hip biomechanics of individual patients.

From Stryker 10 Feb 2010

Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications

Daiichi Sankyo Company, Limited, announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

3 Feb 2010

New technique could eliminate hip replacement surgeries in young trauma patients

A novel surgery using transplanted bone and cartilage may help young patients avoid a hip replacement after a specific traumatic injury to the hip joint, according to a case study by orthopedic trauma specialists at Hospital for Special Surgery in New York. The study appears in the February issue of the Journal of Orthopaedic Trauma.

28 Jan 2010

Zimmer Holdings reports net sales of $1.11 billion for the fourth-quarter of 2009

Zimmer Holdings, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company reported fourth quarter net sales of $1.11 billion, an increase of 7.5% reported and 2.5% constant currency over the fourth quarter of 2008. Diluted earnings per share for the quarter were $0.74 reported and $1.12 adjusted, an increase of 12.0% adjusted over the prior year period.